Canada markets closed

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.4300-0.2300 (-4.94%)
At close: 04:00PM EDT
4.5700 +0.14 (+3.16%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.6600
Bid4.4200 x 900
Ask4.5700 x 2200
Day's Range4.3900 - 4.9900
52 Week Range0.2700 - 34.0000
Avg. Volume166,546
Market Cap26.36M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.8080
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.00
  • GlobeNewswire

    Abeona Therapeutics Reports Second Quarter 2022 Financial Results

    Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VIITAL™ reveal significant scope for pain reduction and EB-101 differentiation NEW YORK and CLEVELAND, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announ

  • GlobeNewswire

    Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

    NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. In order to regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closin

  • Zacks

    F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

    Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.